Header Logo

RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes.

RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes. Oncotarget. 2015 Nov 03; 6(34):36522-34.

View in: PubMed